JCI Editor’s update, December 2019

Dear Colleague,

As the year draws to a close, I wanted to take the opportunity to update you on recent JCI activity. The Journal continues to build on its history of publishing outstanding biomedical research, garnering wide attention in the scientific literature, the press, and social media (highlighted below). In particular, the Clinical Medicine category, now in its seventh year, continues to flourish, with 25 articles published in 2019. Among these were two of the highest-cited JCI papers of the year, on the role of androgen receptor splice variant-7 in castration-resistant prostate cancer; and the use of B cell maturation antigen–targeted CAR T cells in multiple myeloma. We welcome submissions from ASCI members reporting new medical therapies, interventions, diagnostic advances, or observational studies in humans that have the potential to change medical practice.

Viewpoint articles have given voice to experts and thought leaders in medicine, academia, nonprofit organizations, industry, and representatives of the JCI and ASCI on subjects of topical and long-term interest. In one recent Viewpoint (available here), the women on the JCI Editorial Board share their perspective on achieving equity for women and underrepresented minorities in academic medicine leadership, including in societies and journals. In another, Kieren Marr (2018-19 ASCI President) et al. discuss the Society’s strategic support of physician-scientists. In early January, look for a series of Viewpoints on the effects of climate change on human health.

The Journal published four Review Series this year, on mechanisms underlying the metabolic syndrome, reparative immunology, allergy, and familial cancer predisposition syndromes, the latter three with series editors who are ASCI members. Individual Reviews covered a range of subjects, from vaccines to endocrinology to neurology, including a highly cited article on the functional significance of platelet immune receptors.

Reminders:

• ASCI members who are the corresponding author of a first-round submission to the JCI, and whose dues are current, may designate one submission per calendar year to be guaranteed for external peer review. For details, visit the For Authors page.
• Authors may transfer manuscripts from the preprint server bioRxiv for submission to the JCI.

I wish you all the best for the New Year, and look forward to reading your best work.

Sincerely,

Rexford S. Ahima, MD, PhD
Editor, The Journal of Clinical Investigation

The JCI in selected news outlets, 2019

Source: Altmetric. Corresponding authors who are ASCI members are indicated in bold.

Social media activity: Twitter

Source: Altmetric, November 2019. Corresponding authors who are ASCI members are indicated in bold.